Login to Your Account

UK's Labyrinthine Regulations Stalling Regenerative Medicine

By Nuala Moran
Staff Writer

Wednesday, July 3, 2013
LONDON – Problems with the regulatory framework and a lack of coordination is holding back development of regenerative therapies, delaying both health and economic benefits. Changes are needed to give investors confidence and clear the path to commercialization, according to a report on regenerative medicine in the UK, published last week. Private investors are reluctant to put money into regenerative medicine because of the high risk of failure to translate promising science into reimbursable treatments.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription